Pulling SEC filings + quote and writing the call…

Drugs Made In America Acquisition Corp.
Next earnings Aug 3, 2026
Pre-deal Cayman blank-check SPAC with no business, negative equity, and no announced target — a bet on a merger that may never come.
Price $0.11 · latest
DMAAR is not an operating company — it is a Cayman Islands blank-check SPAC incorporated May 23, 2024 that, in its own words, has 'neither engaged in any operations nor generated any operating revenues to date.' The FY2025 'net income' of $5.94M is an accounting artifact: $8.76M of interest earned on the ~$231.15M trust account, offset by $2.82M of G&A that itself includes a $2.0M non-cash share-issuance expense (200,000 shares handed to a sponsor investor for no consideration). Operating income is actually -$2.82M and operating cash flow is -$539K. There is no revenue line and, per the filing, none is expected until a business combination closes. This is a shell whose entire value proposition is a deal that has not been announced.
The balance sheet reads alarmingly on the surface — stockholders' equity of -$7.26M against $240M of assets — but that is standard SPAC optics: the ~$231M of redeemable trust shares sit outside permanent equity, and $6.9M of deferred underwriting fees plus other accruals drive the $7.28M of liabilities. Operating cash is a rounding error at $6,137. So the company itself is solvent only via the trust; the public equity holder's claim is essentially the ~$10.00/share redemption value in trust, NOT the reported book equity.
Is DMAAR a buy? The one-page verdict, explained →
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY25 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$2.82M |
| Net income | $5.94M |
| Diluted EPS | — |
| Net margin | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Q1'26: still a shell earning trust interest, no target closed yet
Entered a new material definitive agreement (Item 1.01)
Shareholder vote: charter amendment/extension approved to keep SPAC alive
Signed another material definitive agreement (Item 1.01)
FY25 net income $5.9M on trust interest; no target, going-concern risk
Proxy for shareholder meeting, likely combination-deadline extension
Disclosed an other-events update (Item 8.01)
Notified SEC the annual 10-K would be filed late
New agreement plus a direct financial obligation (loan/note) incurred
Sources: SEC EDGAR (CIK 0002028614, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/4/2026, 10:34:53 AM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:34 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2025-02-18 | Drugs Made In America Acquisition LLC 10% owner | Buy | 30.0K | |
| 2025-02-18 | Stockwell Lynn CEO and Exe. Chair of Board | Buy | 30.0K | |
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Buy | 400K | |
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Disposed (J) | 400K | |
| 2025-01-29 | Drugs Made In America Acquisition LLC 10% owner | Sell | 5.70M | |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Buy | 400K | |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Disposed (J) | 400K | |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Sell | 5.70M | |
| 2025-01-29 | Shulgan Myron W. Director | Acquired (J) | 100K | |
| 2025-01-29 | Prasad Sridhar G. Director | Acquired (J) | 100K | |
| 2025-01-29 | Do Catherine Director | Acquired (J) | 100K | |
| 2025-01-29 | Worman Glenn C. CFO | Acquired (J) | 100K |
1195 tracked peers · median